Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.

Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing ...

Beyond GSBR-1290, Structure is progressing with the development of an orally administered small molecule amylin receptor agonist for obesity treatment. The company aims to finalize a development ...

Researchers from Columbia University Irving Medical Center published data from a study that assessed GiGA1, a selective G protein-gated inwardly rectifying potassium channel (GIRK) activator, in ...

ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...

Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally ...